Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 28, 2018

LabCorp introduces new UltraQual assay to detect viruses

Life sciences firm LabCorp has launched the new UltraQual Multiplex PCR Assay in the US for the detection of viruses in donated blood plasma, following the US Food and Drug Administration (FDA) approval.

Life sciences firm LabCorp has launched the new UltraQual Multiplex PCR Assay in the US for the detection of viruses in donated blood plasma, following the US Food and Drug Administration (FDA) approval.

Developed by the National Genetics Institute (NGI) laboratory, the test is designed to simultaneously identify hepatitis C virus (HCV), human immunodeficiency virus (HIV) 1 and 2, and hepatitis B virus (HBV) in a single sample.

“These plasma-derived therapies, known as biologics, replace missing or deficient proteins in a patient’s plasma to treat various well-defined medical conditions.”

When combined with NGI’s process to enhance testing throughput, UltraQual is said to offer improved turnaround time and value.

The assay is intended to aid biopharmaceutical companies that manufacture plasma-derived therapies in assessing the safety and availability of their medicines.

These plasma-derived therapies, known as biologics, replace missing or deficient proteins in a patient’s plasma to treat various well-defined medical conditions.

LabCorp Diagnostics chief scientific officer Marcia Eisenberg said: “This next-generation technology offers the international biopharmaceutical industry a differentiated solution to improve plasma donor collection programmes and the manufacturing of plasma protein therapies for a variety of life-threatening conditions including bleeding, immune, cardio/pulmonary and neurological disorders.”

Content from our partners
“Everything is custom”: Behind the scenes of medical wire solutions
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials

In March this year, LabCorp’s Covance Drug Development unit launched an immunology and immunotoxicology (I&I) unit focussed on catering to global biologic drug development needs.

The I&I unit, Covance’s expanded laboratory footprint, and LabCorp Diagnostics’ boost to its biologic therapeutic drug monitoring tests range are expected to support the company’s strategy to develop and commercialise new services for biologics market.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU